High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.

Boeree, Martin J; Heinrich, Norbert; Aarnoutse, Rob; Diacon, Andreas H; Dawson, Rodney; Rehal, Sunita; Kibiki, Gibson S; Churchyard, Gavin; Sanne, Ian; Ntinginya, Nyanda E; +20 more... Minja, Lilian T; Hunt, Robert D; Charalambous, Salome; Hanekom, Madeleine; Semvua, Hadija H; Mpagama, Stellah G; Manyama, Christina; Mtafya, Bariki; Reither, Klaus; Wallis, Robert S; Venter, Amour; Narunsky, Kim; Mekota, Anka; Henne, Sonja; Colbers, Angela; van Balen, Georgette Plemper; Gillespie, Stephen H; Phillips, Patrick PJ; Hoelscher, Michael; PanACEA consortium; (2016) High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. The Lancet infectious diseases, 17 (1). pp. 39-49. ISSN 1473-3099 DOI: https://doi.org/10.1016/S1473-3099(16)30274-2

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1016/S1473-3099(16)30274-2

Abstract

Share

Download

Filename: High-dose rifampicin, moxifloxacin, and SQ109.pdf

Licence: Creative Commons: Attribution 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar